Platelet Rich Plasma as a Treatment For Resistant Corneal Ulcers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

14 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-01-01

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This prospective study involved 14 patients aged \> 18 years with RCUs not responding to conventional treatment. All patients were treated with E-PRP drops (one drop), preservative-free artificial tears, antibiotic eye drop four times daily and systemic vitamin A once daily for one month. All patients were examined at 1, 2, 4, 6 and 8 weeks after the treatment initiation. In each visit, the following parameters were assessed: best corrected visual acuity (BCVA), anterior segment, corneal healing, condition of the conjunctiva, presence of abnormal discharge and symptoms reported.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Platelet Rich Plasma in Corneal Surface Diseases

NCT05320172

Persistent Corneal Epithelial Defects Dry Eye

UNKNOWN PHASE3

Perforated Punctal Plugs for Treatment of Papillary Conjunctivitis in Otherwise Healthy Patients

NCT02503956

Epiphora Conjunctivitis

COMPLETED NA

Autologous Platelet Lysate in Corneal Epithelial Defects

NCT02979912

Persistent Corneal Epithelial Defect

COMPLETED PHASE1/PHASE2

Compare of PRP Autologous Serum and Autologous Serum by Intrastromal Injection in Different Eye Disease Conditions

NCT05944757

PRP

UNKNOWN NA

Evaluating the Use of ProKera Plus® in the Management of Bacterial Corneal Ulcers

NCT04850313

Bacterial Corneal Ulcer

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The present prospective study involved 14 patients aged \> 18 years with RCUs not responding to conventional treatment. All patients were treated with E-PRP drops (one drop), preservative-free artificial tears, antibiotic eye drop four times daily and systemic vitamin A once daily for one month. All patients were examined at 1, 2, 4, 6 and 8 weeks after the treatment initiation. In each visit, the following parameters were assessed: best corrected visual acuity (BCVA), anterior segment, corneal healing, condition of the conjunctiva, presence of abnormal discharge and symptoms reported.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cornea Ulcer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Autologous platelet-rich plasma eye drops

Autologous platelet-rich plasma eye drops are derived from treatment of patients plasma using special process.

Group Type EXPERIMENTAL

Autologous platelet-rich plasma (PRP) eye drops

Intervention Type BIOLOGICAL

Autologous platelet-rich plasma (PRP) eye drops are used as a sole or adjunctive therapy in many ophthalmological conditions including dry eye, macular holes, retinitis pigmentosa and perforated corneal ulcers. Actions of PRP in these conditions are attributed to the plethora of growth and healing factors concentrated in different PRP preparations.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Autologous platelet-rich plasma (PRP) eye drops

Autologous platelet-rich plasma (PRP) eye drops are used as a sole or adjunctive therapy in many ophthalmological conditions including dry eye, macular holes, retinitis pigmentosa and perforated corneal ulcers. Actions of PRP in these conditions are attributed to the plethora of growth and healing factors concentrated in different PRP preparations.

Intervention Type BIOLOGICAL